A Randomised phase II study with the combination of Xeloda (Capecitabine) plus Navelbine Oral ( Vinorelbine) day 1 and day 8 every 3. week versus Xeloda plus Navelbine Oral given metronimic as 1. or 2. line chemotherapy to patients with HER2 negative local metastatic breastcancer.
Phase of Trial: Phase II
Latest Information Update: 03 Nov 2016
At a glance
- Drugs Capecitabine (Primary) ; Vinorelbine (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms XeNa
- 27 Oct 2016 Status changed to completed.
- 15 Sep 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01941771).
- 22 Feb 2012 New trial record